Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02568449 · OUTCOME

Number of Participants Responded (Complete Response, Partial Response, Stable Disease, Progressive Disease, Not Evaluable)

Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent · Source last updated 2021-12-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 1 year

What was measured

number of participants responded (complete response, partial response, stable disease, progressive disease, not evaluable) per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0)

Groups in this outcome

Treatment (Nintedanib)

Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Nintedanib: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Nintedanib)20

Reported measurements

complete response
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Nintedanib)0Not reportedNot reportedNot reportedNot reported
partial response
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Nintedanib)0Not reportedNot reportedNot reportedNot reported
stable disease
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Nintedanib)0Not reportedNot reportedNot reportedNot reported
progressive disease
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Nintedanib)18Not reportedNot reportedNot reportedNot reported
not evaluable
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Nintedanib)2Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    complete response
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    partial response
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    stable disease
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        18
    title
    progressive disease
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    not evaluable
denoms
  1. counts
    1. group Id
      OG000
      value
      20
    units
    Participants
description
number of participants responded (complete response, partial response, stable disease, progressive disease, not evaluable) per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0)
groups
  1. description
    Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Nintedanib: Given PO
    id
    OG000
    title
    Treatment (Nintedanib)
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Up to 1 year
title
Number of Participants Responded (Complete Response, Partial Response, Stable Disease, Progressive Disease, Not Evaluable)
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice